Pacira BioSciences Yönetim

Yönetim kriter kontrolleri 2/4

Pacira BioSciences CEO'su Frank Lee, Jan2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.018% doğrudan sahiptir ve bu hisselerin değeri € 138.20K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 5.2 yıldır.

Anahtar bilgiler

Frank Lee

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	5.2yrs

Son yönetim güncellemeleri

Recent updates

CEO

Frank Lee (56 yo)

less than a year

Görev süresi

Mr. Frank D. Lee served as an Independent Director at Bolt Biotherapeutics, Inc. since November 2021 until September 2024. He is Independent Director of Bausch Health Companies Inc. from May 14, 2024. He i...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daryl Gaugler	Chief Operating Officer	2.5yrs	US$1.53m	0.027% € 206.4k
Kristen Williams	Chief Administrative Officer & Secretary	10.1yrs	US$1.60m	0% € 0
David Stack	Advisor	less than a year	US$6.88m	0.51% € 4.0m
Charles Reinhart	Executive Officer	less than a year	US$1.43m	0.059% € 462.2k
Jonathan Slonin	Chief Medical Officer	3.3yrs	US$1.59m	0.028% € 218.7k
Frank Lee	CEO & Director	less than a year	Veri yok	0.018% € 139.3k
Shawn Cross	Chief Financial Officer	less than a year	Veri yok	Veri yok
Lauren Riker	Principal Accounting Officer & Senior VP of Finance	12.7yrs	US$288.82k	0.0046% € 36.0k
Susan Mesco	Head of Investor Relations	no data	Veri yok	Veri yok
Anthony Molloy	Chief Legal & Compliance Officer	2.9yrs	US$2.05m	0.028% € 217.0k
Richard Kahr	Vice President of Human Resources	9.3yrs	Veri yok	Veri yok
Christopher Young	Chief Manufacturing Officer	1.6yrs	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: 82P 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Frank Lee	CEO & Director	less than a year	Veri yok	0.018% € 139.3k
Laura Brege	Independent Director	13.4yrs	US$364.01k	0.027% € 207.7k
Paul Hastings	Chairman of the Board	13.4yrs	US$390.51k	0.016% € 126.3k
Andreas Wicki	Independent Director	17.9yrs	Veri yok	Veri yok
Mark Kronenfeld	Independent Director	11.4yrs	US$373.01k	0.043% € 331.5k
Christopher Christie	Independent Director	5.2yrs	US$325.01k	0.011% € 88.6k
Alethia Young	Independent Director	1.1yrs	US$427.86k	0% € 0
Marcelo Bigal	Independent Director	1.1yrs	US$426.45k	0.011% € 82.8k
Abraham Ceesay	Independent Director	1.1yrs	US$427.16k	0% € 0
Mark Froimson	Independent Director	7.4yrs	US$349.01k	0.020% € 155.8k
Michael Yang	Independent Director	1.1yrs	US$427.16k	0.0043% € 33.7k

5.2yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 82P 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.2 yıldır).

Pacira BioSciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Pacira BioSciences, Inc. Announces Chief Financial Officer Changes

Pacira Biosciences, Inc. Announces Board Changes

CEO & Director recently bought €91k worth of stock

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Independent Director recently sold €3.3m worth of stock

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Recent updates

Pacira BioSciences, Inc. Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Third quarter 2024 earnings released: US$3.11 loss per share (vs US$0.23 profit in 3Q 2023)

Pacira BioSciences, Inc. Reports Goodwill Impairment for the Third Quarter Ended September 30, 2024

Pacira BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Pacira BioSciences, Inc. Announces Chief Financial Officer Changes

Pacira BioSciences, Inc. Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

DOMA Perpetual Capital Management Sends Letter to the Board of Directors of Pacira Biosciences

Pacira Biosciences, Inc. Announces Board Changes

Investor sentiment deteriorates as stock falls 42%

CEO & Director recently bought €91k worth of stock

New major risk - Share price stability

Second quarter 2024 earnings released: EPS: US$0.41 (vs US$0.56 in 2Q 2023)

Pacira BioSciences, Inc. to Report Q2, 2024 Results on Jul 30, 2024

Investor sentiment deteriorates as stock falls 23%

Pacira BioSciences, Inc. (NasdaqGS:PCRX) announces an Equity Buyback for $150 million worth of its shares.

Pacira BioSciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold €3.3m worth of stock

Full year 2023 earnings released: EPS: US$0.91 (vs US$0.35 in FY 2022)

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

High number of new directors

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: EPS: US$0.56 (vs US$0.44 in 2Q 2022)

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Chief Financial Officer recently sold €854k worth of stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings released: US$0.42 loss per share (vs US$0.15 profit in 1Q 2022)

Now 21% undervalued

Full year 2022 earnings released: EPS: US$0.35 (vs US$0.95 in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Insufficient new directors

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

Pacira Biosciences, Inc. Announces Positive Topline Data from Phase 3 Study of EXPAREL as A Single-Dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

Pacira BioSciences, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacira Biosciences, Inc. Not to Provide Revenue Guidance for the Fiscal Year 2022

Chief Clinical Officer recently sold €52k worth of stock

Chairman & CEO recently sold €687k worth of stock

Independent Director recently sold €56k worth of stock

First quarter 2022 earnings released: EPS: US$0.15 (vs US$0.24 in 1Q 2021)

Insufficient new directors

Pacira BioSciences, Inc., Annual General Meeting, Jun 07, 2022

Pacira BioSciences, Inc. Provides Preliminary Revenue Guidance for the First Quarter of 2022

Insufficient new directors

Pacira BioSciences, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: EPS US$0.40 (vs US$3.03 in 3Q 2020)

Pacira BioSciences, Inc Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries

Second quarter 2021 earnings released: EPS US$0.43 (vs US$0.17 loss in 2Q 2020)

Insufficient new directors

Pacira Biosciences, Inc. Announces FDA Approval of Enhanced Exparel Manufacturing Process

Pacira BioSciences, Inc.(NasdaqGS:PCRX) dropped from Russell 2000 Growth-Defensive Index

Pacira BioSciences, Inc. Announces Top-Line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block

Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021

Pacira Biosciences, Inc. Announces That Product Sales Continue to Be Negatively Impacted by the Covid-19 Pandemic for the Full Year 2021

Full year 2020 earnings released: EPS US$3.41 (vs US$0.27 loss in FY 2019)